News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transition Therapeutics Inc. (TTH.TO) Announces ELND005 Presentations at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies


5/14/2012 9:49:25 AM

TORONTO, May 14, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced today that a mini-symposium entitled "The Emerging Clinical Profile of Oral Scyllo-inositol (ELND005) in Alzheimer's Disease: A Dual Mechanism of Action?" was held on Saturday, May 12th, 2012 at the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapies. Elan Pharmaceuticals, Inc. has responsibility for the development and commercialization of ELND005. This mini-symposium consisted of the five following presentations:

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES